Teva gets FDA approval for once-monthly schizophrenia shot
Teva said the FDA approved Weltruza, a once-monthly injectable treatment for schizophrenia. The company said it is the first under-the-skin shot of its kind for the disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Teva shares rise after FDA approval for Weltruza schizophrenia drug
Teva’s affiliate said the FDA approved Weltruza, an extended-release injectable suspension, for treating schizophrenia in adults. The stock was up about 6% to $41.56 in morning trade.